Manchester Capital Management’s 10x Genomics TXG Stock Holding History

Manchester Capital Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.3K	Hold	61	–	–	﹤0.01%	1089
2025 Q4	$995	Buy	+61	New	+$921	﹤0.01%	1138
2025 Q2	–	Sell	-4	Closed	-$35	–	1237
2025 Q1	$35	Hold	4	–	–	﹤0.01%	1166
2024 Q4	$58	Hold	4	–	–	﹤0.01%	1147
2024 Q3	$91	Hold	4	–	–	﹤0.01%	1165
2024 Q2	$78	Hold	4	–	–	﹤0.01%	1143
2024 Q1	$151	Hold	4	–	–	﹤0.01%	1013
2023 Q4	$224	Hold	4	–	–	﹤0.01%	974
2023 Q3	$165	Hold	4	–	–	﹤0.01%	971
2023 Q2	$224	Buy	+4	New	+$216	﹤0.01%	923
2021 Q1	–	Sell	-3	Closed	–	–	790
2020 Q4	$0	Buy	+3	New	+$435	﹤0.01%	783

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Manchester Capital Management's TXG Position: Q1 2026 in Review

Manchester Capital Management held its 10x Genomics (TXG) position steady in Q1 2026 at 61 shares worth $1.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1089.

Manchester Capital Management first reported a position in TXG in Q4 2020 and has held it in 11 quarters since. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

Manchester Capital Management held 61 shares of 10x Genomics worth $1.3K as of Q1 2026.
Manchester Capital Management left its 10x Genomics share count unchanged in Q1 2026.
10x Genomics made up ﹤0.01% of Manchester Capital Management's portfolio in Q1 2026, its #1089 holding.
Manchester Capital Management first reported a position in 10x Genomics in Q4 2020 and has held it in 11 quarters since.
329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Manchester Capital Management's 13F filing for Q1 2026, filed 11 May 2026.